This inventor holds 7 USPTO granted patents and 1 EPO patent. Top assignees: Wyeth, Ortho-Mcneil Pharmaceutical Corp., Wyeth Holdings Corporation. Active years: 2005-2010.
Company Filing History:
5 out of 1,309 
1 out of 363 
1 out of 113 Years Active: 2005-2010
Title: Scott Mason Duncan: Innovator in Antineoplastic Combinations
Introduction
Scott Mason Duncan is a notable inventor based in Madison, WI (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of antineoplastic combinations. With a total of 7 patents to his name, Duncan's work has the potential to impact cancer treatment significantly.
Latest Patents
Among his latest patents, Duncan has developed innovative antineoplastic combinations. One of his notable inventions provides the use of a combination of CCI-779 and EKB-569 in the treatment of neoplasms. This combination aims to enhance the efficacy of cancer therapies and improve patient outcomes.
Career Highlights
Throughout his career, Scott Mason Duncan has worked with prominent companies in the pharmaceutical industry, including Wyeth and Ortho-McNeil Pharmaceutical Corporation. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in cancer treatment.
Collaborations
Duncan has collaborated with several professionals in his field, including Sylvain Daigneault and John Leo Considine. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Scott Mason Duncan's contributions to the field of antineoplastic combinations highlight his dedication to improving cancer treatment. His innovative patents and collaborations with industry professionals underscore his role as a significant figure in pharmaceutical research.